Dr Reddy's Laboratories Ltd-ADR
Затворен
СекторЗдравеопазване
13.24 1.46
Преглед
Промяна на цената на акция
24 ч
Минимум
13.02
Максимум
13.33
Приходи | -9.7B 2.2B |
|---|---|
Продажби | -11B 76B |
P/E Средно за сектора | 24.556 49.888 |
Дивидентна доходност | 0.63 |
Марж на печалбата | 2.928 |
Служители | 27,527 |
EBITDA | -13B 6.1B |
Дивидентна доходност Средно за сектора | 0.63% 2.38% |
|---|
Пазарна капитализация | 68M 11B |
|---|---|
Предишно отваряне | 11.78 |
Предишно затваряне | 13.24 |
Настроения в новините
By Acuity
50%
50%
155 / 344 Класиране в Healthcare
Dr Reddy's Laboratories Ltd-ADR Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Dr Reddy's Laboratories Ltd-ADR Прогноза
Настроение
By Acuity
155 / 344 Класиране в Здравеопазване
Настроения в новините
Neutral
Волатилност
Под средното
Обем новини (RCV)
Среден
Финанси
Продажбени и админисративни разходи
Оперативни разходи
Печалба преди облагане с данъци
Продажби
Разходи за продажби
Брутна печалба от продажби
Разходи за лихви по дълг
EBITDA
Оперативна печалба
$
Относно Dr Reddy's Laboratories Ltd-ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.